The neurogenic bladder: Medical treatment

Pediatric Nephrology

Volumn 23, Issue 5, 2008, Pages 717-725

  Verpoorten, Carla ^a   Buyse, Gunnar M ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Anticholinergics; Intermittent catheterization; Neurogenic bladder; Urinary continence; Urodynamics

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROPIVERINE; TOLTERODINE; TROSPIUM; UNCLASSIFIED DRUG; URINARY TRACT AGENT;

ARTICLE; BLADDER CAPACITY; BLADDER CATHETERIZATION; BLADDER INNERVATION; BLADDER PRESSURE; BLADDER SURGERY; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; ELECTROMYOGRAPHY; FECES INCONTINENCE; FIRST PASS EFFECT; FOLLOW UP; HIGH RISK PATIENT; HUMAN; KIDNEY INJURY; MAXIMUM PERMISSIBLE DOSE; NEUROGENIC BLADDER; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SPINA BIFIDA; UNSPECIFIED SIDE EFFECT; URINALYSIS; URINE INCONTINENCE; URODYNAMICS;

CHILD; CHOLINERGIC ANTAGONISTS; HUMANS; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY CATHETERIZATION; URODYNAMICS; UROLOGIC SURGICAL PROCEDURES;

EID: 41749094949     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-007-0691-z     Document Type: Article

References (56)

1. Lapides J, Diokno AC, Silber SJ, Lowe BS (1972) Clean intermittent self-catheterization in the treatment of urinary tract disease. J Urol 107:458-461
2. McGuire EJ, Woodside JR, Bordin TA, Weiss RM (1981) Prognostic value of urodynamic testing in myelodysplastic patients. J Urol 136:205-209
3. Bauer SB, Hallet M, Khoshbin S, Lebowitz RL, Winston KR, Gibson S, Colodny AH, Retik AB (1984) Predictive value of urodynamic evaluation in newborns with myelodysplasia. JAMA 252:650-652
4. Sidi AA, Peng W, Gonzalez R (1986) Vesicoureteral reflux in children with myelodysplasia: Natural history and results of treatment. J Urol 136:329-331
5. Smith ED (1972) Urinary prognosis in spina bifida. J Urol 108:815-817
6. van Gool JD (1986) Spina bifida and neurogenic bladder dysfunction - a urodynamic study. Utrecht, Impress
7. Stephenson TP, Wein AJ (1986) The interpretation of urodynamics. In Mundy AR, Stephenson TP, Wein A (eds) Urodynamics: Principles, practice and application. Churchill Livingstone, Edinburgh
8. Wang SC, McGuire EJ, Bloom DA (1988) A bladder pressure management system for myelodysplasia-clinical outcome. J Urol 140:1499-1502
9. Steinhardt GF, Goodgold HM, Samuels LD (1988) The effect of intravesical pressure on glomerular filtration rate in patients with myelomeningocele. J Urol 140:1293-1295
10. Rickwood AM, Thomas DG, Philp NH, Spicer RD (1982) Assessment of congenital neurovesical dysfunction by combined urodynamic and radiological studies. Br J Urol 54:512-518
11. Bauer SB, Joseph DB (1990) Management of the obstructed urinary tract associated with neurogenic bladder dysfunction. Urol Clin North Am 17:395-406
12. van Gool JD (1982) Detrusor-sphincter dyssynergia in children with myelomeningocele: A prospective study. Z Kinderchir 37:148-152
13. Mundy AR, Borzyskowski M, Saxton HM (1982) Videourodynamic evaluation of neuropathic vesicoureteral dysfunction in children. J Urol 54:645-649
14. Snodgrass WT, Adams R (2004) Initial urologic management of myelomeningocele. Urol Clin North Am 31:427-434
15. Baskin LS, Kogan BA, Benard F (1990) Treatment of infants with neurogenic bladder dysfunction using anticholinergic drugs and intermittent catheterisation. Br J Urol 66:532-534
16. Fernandes E, Reinberg Y, Vernier R, Gonzales R (1994) Neurogenic bladder dysfunction in children: Review of pathophysiology and current management. J Pediatr 124:1-7
17. Jeruto A, Poenaru D, Bransford R (2004) Clean intermittent catheterisation: Overview of results in 194 patients with spina bifida. Afr J Pediatr Surg 1:20-23
18. Kari JA (2006) Neuropathic bladder as a cause of chronic renal failure in children in developing countries. Pediatr Nephrol 21:517-520
19. Spindel MR, Bauer SB, Dyro FM, Krarup C, Koshbin S, Winston KR, Lebowitz RL, Colodny AH, Retik AB (1987) The changing neurourologic lesion in myelodysplasia. JAMA 258:1630-1633
20. Tarcan T, Bauer S, Olmedo E, Khoshbin S, Kelly M, Darbey M (2001) Long-term followup of newborns with myelodysplasia and normal urodynamic findings: Is follow-up necessary? J Urol 165:564-567
21. Kurzrock EA, Polse S (1998) Renal deterioration in myelodysplastic children: Urodynamic evaluation and clinical correlates. J Urol 159:1657-1661
22. Teichman JM, Scherz HC, Kim KD, Cho DH, Packer MG, Kaplan GW (1994) An alternative approach to myelodysplasia management: Aggressive observation and prompt intervention. J Urol 152:807-811
23. Hopps CV, Kropp KA (2003) Preservation of renal function in children with myelomeningocele managed with basic newborn evaluation and close follow-up. J Urol 169:305-308
24. Joseph DB (1992) The effect of medium-fill and slow-fill saline cystometry on detrusor pressure in infants and children with myelodysplasia. J Urol 147:444-446
25. Bauer SB, Reda EF, Colodny AH, Retik AB (1986) Detrusor instability: A delayed complication in association with the artificial sphincter. J Urol 135:1212-1215
26. Blaivas JG, Labib KL, Bauer SB, Retik AB (1977) A new approach to electromyography of the external urethral spincter. J Urol 117:773-777
27. Joseph DB, Bauer SB, Colodny AH, Mandell J, Retik AB (1989) Clean intermittent catheterization of infants with neurogenic bladder. Pediatrics 84:78-82
28. van Gool JD, Dik P, de Jong TP (2001) Bladder sphincter dysfunction in myelomeningocele. Eur J Pediatr 160:414-420
29. Kessler TM, Lackner J, Kiss G, Rehder P, Madersbacher H (2006) Early proactive management improves upper urinary tract function and reduces the need for surgery in patients with myelomeningocele. Neurourol Urodyn 25:758-762
30. Schlager TA, Clark M, Anderson S (2001) Effects of single-use sterile catheter for each void on the frequency of bacteriuria in children with neurogenic bladder on intermittent catheterization for bladder emptying. Pediatrics 108:E71
31. Sutherland RS, Kogan BA, Baskin LS, Mevorach RA (1996) Clean intermittent catheterization in boys using the LOFric catheter. J Urol 156:2041-2043
32. De Swert LF, Van Laer KM, Verpoorten CM, Van Hoeyveld EM, Cadot P, Stevens EA (1997) Determination of independent risk factors and comparative analysis of diagnostic methods for immediate type latex allergy in spina bifida patients. Clin Exp Allergy 27:1067-1076
33. Edelstein RA, Bauer SB, Kelly MD, Darbey MM, Peters CA, Atala A, Mandell J, Colodny AH, Retik AB (1995) The long-term urological response of neonates with myelodysplasia treated proactively with intermittent catheterization and anticholinergic therapy. J Urol 154:1500-1504
34. Andersson KE, Chapple CR (2001) Oxybutynin and the overactive bladder. World J Urol 19:319-323
35. Kaefer M, Pabby A, Kelly M, Darbey M, Bauer SB (1999) Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomeningocele. J Urol 162:1068-1071
36. Aslan AR, Kogan BA (2002) Conservative management in neurogenic bladder dysfunction. Curr Opin Urol 12:473-477
37. Dik P, Klijn AJ, van Gool JD, de Jong-de Vos van Steenwijk CC, de Jong TP (2006) Early start to therapy preserves kidney function in spina bifida patients. Eur Urol 49:908-913
38. Brendler CB, Radebaugh LC, Mohler JL (1989) Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 141:1350-1352
39. Madersbacher H, Jilg G (1991) Control of detrusor hyperreflexia by the intravesical instillation of oxybutynin hydrochloride. Paraplegia 29:84-90
40. Buyse G, Verpoorten C, Vereecken R, Casaer P (1995) Treatment of neurogenic bladder dysfunction in infants and children with neurospinal dysraphism with clean intermittent (self) catheterisation and optimized intravesical oxybutynin hydrochloride therapy. Eur J Pediatr Surg 5:31-34
41. Buyse G, Verpoorten C, Vereecken R, Casaer P (1998) Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. J Urol 160:1084-1087
42. Amark P, Bussman G, Eksborg S (1998) Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. Eur Urol 34:148-153
43. Haferkamp A, Staehler G, Gerner HJ, Dörsam J (2000) Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. Spinal Cord 38:250-254
44. Fratta A, Bordenave J, Boissinot C, Le Grand J, Esquirol C, Radideau E, Benoit G (2005) Development of an intravesical oxybutynin chloride solution: From formulation to quality control. Ann Pharm Fr 63:162-166
45. Buyse G, Waldeck K, Verpoorten C, Björk H, Casaer P, Andersson KE (1998) Intravesical oxybutynin for neurogenic bladder dysfunction: Less systemic side effects due to reduced first pass metabolism. J Urol 160:892-896
46. De Wachter S, Wyndaele JJ (2003) Intravesical oxybutynin: A local anesthetic effect on bladder C afferents. J Urol 169:1892-1895
47. Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB (2005) Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder afferent pathways. Urology 65:238-242
48. Youdim K, Kogan BA (2002) Preliminary study of the safety and efficacy of extended-release oxybutynin in children. Urology 59:428-432
49. Goessl C, Sauter T, Michael T, Bergé B, Staehler M, Miller K (2000) Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. Urology 55:414-418
50. Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdörfer H, Göcking K, Madersbacher H, Schumacher S, Richter R, von Tobel J, Schurch B (2004) European experience of 200 cases treated with Botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510-515
51. Altaweel W, Jednack R, Bilodeau C, Corcos J (2006) Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol 175:1102-1105
52. Kasabian NG, Bauer SB, Dyro FM, Colodny AH, Mandell J, Retik AB (1992) The prophylactic value of clean intermittent catheterization and anticholinergic medication in newborns and infants with myelodysplasia at risk of developing urinary tract deterioration. Am J Dis Child 146:840-843
53. Madersbacher H (2002) Neurogenic bladder dysfunction in patients with myelomeningocele. Curr Opin Urol 12:469-472
54. Berger R, Maizels M, Moran G, Conway J, Firlit C (1983) Bladder capacity (ounces) equals age (years) plus 2 predicts normal bladder capacity and aids in diagnosis of abnormal voiding patterns. J Urol 129:347-349
55. Houle AM, Gilmour RF, Churchill BM, Gaumond M, Bissonnette B (1993) What volume can a child normally store in the bladder at a safe pressure? J Urol 149:561-564
56. Liptak GS (2003) Evidence-based practice in spina bifida: Developing a research agenda, May 9-10, 2003, Washington DC